key: cord-0890287-qzu67409 authors: Shadrack, Daniel M.; Deogratias, Geradius; Kiruri, Lucy W.; Swai, Hulda S.; Vianney, John-Mary; Nyandoro, Stephen S. title: Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms date: 2021-02-23 journal: J Mol Graph Model DOI: 10.1016/j.jmgm.2021.107871 sha: 691279652bf4fe9c91278eb90ea4ec4a2d5b8627 doc_id: 890287 cord_uid: qzu67409 The recent outbreak of SARS-CoV-2 is responsible for high morbidity and mortality rate across the globe. This requires an urgent identification of drugs and other interventions to overcome this pandemic. Computational drug repurposing represents an alternative approach to provide a more effective approach in search for COVID-19 drugs. Selected natural product known to have antiviral activities were screened, and based on their hits; a similarity search with FDA approved drugs was performed using computational methods. Obtained drugs from similarity search were assessed for their stability and inhibition against SARS-CoV-2 targets. Diosmin (DB08995) was found to be a promising drug that works with two distinct mechanisms, preventing viral replication and viral fusion into the host cell. Isoquercetin (DB12665) and rutin (DB01698) work by inhibiting viral replication and preventing cell entry, respectively. Our analysis based on molecular dynamics simulation and MM-PBSA binding free energy calculation suggests that diosmin, isoquercetin, rutin and other similar flavone glycosides could serve as SARS-CoV-2 inhibitor, hence an alternative solution to treat COVID-19 upon further clinical validation. on average a drug has 3 targets is highly recommended ]. Identification of potential 56 approved drugs with less side effects serve as a strong basis for drug repurposing ]. The study took advantage of the timely crystallized SARS-CoV-2 structural targets for drug 108 design. The protein structures were obtained from the RCSB protein data bank (PDB) [ was compared with the experimental data and found to be in a reasonable agreement with a 129 Å for all redocked ligands (Fig. S1 ). RMSD of ≤ 3Å was found out to be more reliable and 134 can reproduce the experimental binding mode [Brooijmans(2009) library of 19 natural products (see SI) were blindly screened against SARS-CoV-2 targets, the 137 promising hit compounds with lower binding free energy of −7.5 kcal/mol were selected for 138 further experiments and similarity search. Determination of the best binding energy of small 139 molecules was based on the binding free energy of a co-crystallized ligand that was docked 140 and found to be < −7.5 kcal/mol. In this work, we set the criterion that any ligands with 141 binding free energy ≤ −7.5 kcal/mol similar to inhibition constant of Ki = 3.03 uM to be a 142 potential candidate. Similarity search was performed to repurpose approved drugs so that they 143 can further be evaluated against SARS-CoV-2 target proteins. All a Tanimoto score of 0-1 was used, with 0 depicting no similarity and 1 depicting complete 154 identity. Compounds with higher Tanimoto score of ≥ 0.9 were selected for this study. (1) J o u r n a l P r e -p r o o f where, E MM is the average molecular mechanics energy terms in vacuum which includes 216 bonded and non-bonded interactions, G sol is the free energy of solvation which includes 217 G polar and G non-polar . γ is a coefficient related to surface tension, SASA is the solvent accessible 218 surface area, b is the fitting parameter and T∆S is the entropic contributions to free energy. although the active site is composed of long loops it has few fluctuations (Fig. S2 ). Screening of our in-house library of natural products against this target showed that four 267 ligands: 1, 5, 15 and 17 possessed low binding free energy of ≤ −7.5 kcal/mol (Fig. 2a) . (Fig. 2f, Fig. S7 ) indicated that DB01698 moved out the pocket after 40 ns. Further analysis 322 on the distance and binding mode showed that DB08995 retained its binding pose (Fig. S6a) . In order to ascertain the observed stability, binding free energy based on MM-PBSA was To examine residue contributions to the binding energy of the three ligands, per-residue en- ligand RMSD (Fig. 4b) . Changes in ligand RMSD could be attributed to the large pocket size 395 of the ACE2 receptor. The distance between ligand atoms and receptor residues that formed 396 hydrogen bonds was measured to establish the origin of these changes. As shown in Figure 4c , 397 the sugar moiety 2 (red colour) exhibited more fluctuation within the pocket and it interacted 398 with residues ASP350, GLU401 and GLU402 between the two helices as shown in Figure S9b . To investigate the stability, binding affinity based on MM-PBSA was calculated and results 404 are presented in Table 3 . Binding free energy suggested that DB08995 strongly inhibited ACE2 Screening results against the spike RBD-ACE2 showed that two drugs DB01698 and DB08995 421 could be potent inhibitors. RCS binding free energy showed that the two drugs DB01698 and 422 DB08995 had a mean binding free energy of -9.33 and -9.59 kcal/mol, respectively (Fig. 4d) . 423 Interestingly, DB08995 exhibited two binding poses as compared to DB01698 (Fig. 5a-b) and 424 interacted better with ACE2 residues than DB01698. In order to explain these changes, the distance between the drug and some 445 residue was measured to monitor the stability and changes in binding pose (Fig. 5c-f ). To provide quantitative information, the free energy of the distances was calculated using 447 F = −k B T ln(P (dist)), where F is the free energy, k B is Boltzmann constant, T is temperature 448 and P (dist) is the probability. The free energy showed that DB08995 was bound to spike RBD To obtain crucial insight into the disruptive nature of the DB08995 in relation to the spike RBD-457 ACE2 interface, the distance between RBD and ACE2 was measured for both native and bound 458 protein ( Fig. 6a-b) . Binding of DB08995 induced changes in distance between the two proteins. An increase in distance between the measured residues suggests weak interaction induced by the 460 DB08995 at the interface which implies that spike RBD could weakly interact with ACE2 in the 461 presence of DB08995. Time-lapse binding affinity of DB08995 into its cavity and spike RBD- ACE2 dissociation constant were also calculated so as to gain further understanding about 463 the nature of the drug (Fig. 6c-d) . The binding affinity of DB08995 in its cavity remained 464 stable. However, the dissociation constant between spike RBD-ACE2 increased upon binding 465 of DB08995 which suggests unstable interaction between spike RBD and ACE2. The stability of the proteins was further investigated by analysing the atomic residue fluc- Narayanan, and Chang] and, therefore, it could be a potential candidate to be repurposed 494 for SARS-CoV-2 targeting viral replication. DB01698 is an approved drug used to decrease 495 capillary fragility [Shanno(1946) ]. This drug is also reported to have different pharmacolog- Fast Identification of Possible Drug Treatment of Coronavirus Disease-548 Revealing the molecular mechanisms of 600 proteolysis of SARS-CoV-2 M pro by QM/MM computational methods The SARS-CoV-2 main protease as drug 603 target Fast-growth thermodynamic integration: Error and efficiency 605 analysis Prediction of absolute 611 solvation free energies using molecular dynamics free energy perturbation and the OPLS 612 force field The linear interaction energy method for 614 predicting ligand binding free energies, Combinatorial chemistry & high throughput screen UFF, a full periodic table force field 620 for molecular mechanics and molecular dynamics simulations Open 628 Babel: An open chemical toolbox AutoDock Vina: improving the speed and ac-630 curacy of docking with a new scoring function, efficient optimization, and multithreading, 631 RCSB Protein Data Bank: biological 635 macromolecular structures enabling research and education in fundamental biology The crystal structure of COVID-19 main protease in complex with an inhibitor N3 Structure of the RNA-dependent RNA polymerase from COVID-19 virus The crystal structure of papain-like protease of SARS CoV-2 Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding 651 domain reveals potential unique drug targeting sites The crystal structure of Nsp9 RNA binding protein of SARS CoV-2, RCSB Protein Data 655 Bank ACE2 X-ray structures reveal a large hinge-bending 659 motion important for inhibitor binding and catalysis 663 Structural and functional basis of SARS-CoV-2 entry by using human ACE2 More than a 666 simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the 667 S1 pocket of thrombin Non-additivity of functional group contri-670 butions in protein-ligand binding: a comprehensive study by crystallography and isother-671 mal titration calorimetry Docking methods, ligand design, and validating data sets 673 in the structural genomic era Validation of molecular 677 docking programs for virtual screening against dihydropteroate synthase DrugBank 5.0: a major update to the DrugBank 682 database for PubChem substance and compound databases SwissSimilarity: a web tool for low to ultra high throughput ligand-based 689 virtual screening Density-functional thermochemistry. III. The role of exact exchange 691 Salvetti correlation-energy formula into a functional of the electron density A. Frisch, gaussian 09W Reference Evaluation and reparametrization of 700 the OPLS-AA force field for proteins via comparison with accurate quantum chemical 701 calculations on peptides LigParGen web server: an auto-704 matic OPLS-AA parameter generator for organic ligands Canon-711 ical sampling through velocity rescaling Polymorphic transitions in single 714 crystals: A new molecular dynamics method A smooth particle mesh 718 Ewald method LINCS: a linear constraint solver for molecular simulations Basic ingredients of free energy calculations: a review Pymol: An open-source molecular graphics tool UCSF Chimera-a visualization system for exploratory research and 730 analysis VMD: visual molecular dynamics Scope and limitation of ligand docking: Methods, scoring functions and 736 protein targets Structural basis 739 for the inhibition of SARS-CoV-2 main protease by antineoplastic drug Carmofur Coronavirus nucleocapsid 743 protein is an RNA chaperone p53 degradation by a coronavirus papain-like protease suppresses type I 747 interferon signaling Hypertension, the renin-751 angiotensin system, and the risk of lower respiratory tract infections and lung injury Structure-based discovery of a novel angiotensin-converting 757 enzyme 2 inhibitor The effect of ACE2 inhibitor MLN-4760 on the interac-760 tion of SARS-CoV-2 spike protein with human ACE2: a molecular dynamics study 761 The first-in-class peptide binder to the SARS-CoV-2 spike 764 protein, bioRxiv Computa-766 tional Design of Peptides to Block Binding of the SARS-CoV-2 Spike Struc-769 ture analysis of the receptor binding of 2019-nCoV, Biochemical and biophysical research 770 communications Oligomerization of the SARS-CoV S glycoprotein: dimerization of the 773 N-terminus and trimerization of the ectodomain, Biochemical and biophysical research 774 communications Computational insights into molecular activation and positive 777 cooperative mechanisms of FFAR1 modulators Inhibi-780 tion of influenza virus replication by plant-derived isoquercetin Rutin; a new drug for the treatment of increased capillary 783 fragility The pharmacological poten-785 tial of rutin A. Staniewska, Safety of treatment and dietary Supplementation with dioS-787 min in daily doSeS up to 2000 mg a day Prediction 789 of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening 790 reveals velpatasvir, ledipasvir, and other drug repurposing candidates Silico Molecular Dynamics Docking of Drugs to the Inhibitory 795 Active Site of SARS-CoV-2 Protease and Their Predicted Toxicology and ADME, Available 796 at SSRN 3580951 Flavones: Food sources, bioavailability, metabolism, and bioactivity, Advances 799 in nutrition Characterization of 802 phenolic compounds in some Indian mango cultivars, International journal of food sciences 803 and nutrition Simultaneous determination of 806 all polyphenols in vegetables, fruits, and teas Antidiabetic and antioxidative effects of Annona 809 squamosa leaves are possibly mediated through quercetin-3-O-glucoside • Diosmin is a potent inhibitors of SARS-CoV-2 that work by two distinct mechanisms.• Diosmin disrupt spike RBD-ACE2 recognition and hence preventing viral fusion.• Isoquercetin and rutin work by inhibiting viral replication and preventing cell entry, respectively.J o u r n a l P r e -p r o o f The heading above is refereed.On behalf of all authors, I confirm that all there is no any conflict of interest to all author that can hinder quick and immediate publication of this paper.I thank you for your consideration to publish in your good journal.Dr. Daniel M Shadrack (corresponding author) (On behalf of all authors).